ELREXFIO™ Achieves Median Overall Survival Exceeding Two Years in Relapsed or Refractory Multiple Myeloma Patients

Today, detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) were announced. The study…

Read MoreELREXFIO™ Achieves Median Overall Survival Exceeding Two Years in Relapsed or Refractory Multiple Myeloma Patients